tirzepatide trial At a glance factsheet: for management of type 2 diabetes New research from the SURPASS-EARLY

We have demonstrated in previous studies that in aged rats, LA and ALC were more efficient in combination than individually in ameliorating mitochondrial decay with age, inhibiting oxidative damage, and improving cognitive function and ambulatory activity [2931]

Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]

Comprehensive Wellness Improvement Increased energy and better overall health and vitality, confirmed by patient experiences

Semaglutide and Appetite Control Semaglutide is commonly researched concerning its appetite-controlling properties

Tirzepatide: Known for its potent glycemic control capabilities, tirzepatide has shown significant reductions in HbA1c levels, often surpassing those achieved with other GLP-1 RAs

However, B12 supplementation does support those with hepatitis C and children of pregnant women